Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0000950170-25-062146·Fairmount Funds Management LLC
Schedule 13D ownership disclosure
Jade Biosciences Inc
Common Stock, $0.0001 par value · CUSIP: 008064206
Event date: 2025-04-28
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Fairmount Funds Management LLCReported CIK 0001802528
Shares: 7,249,356 · Class: 19.99%
- Fairmount Healthcare Fund II L.P.Reported CIK 0001769651
Shares: 4,592,551 · Class: 12.66%
- Fairmount Healthcare Co-Invest IV L.P.Reported CIK 0002042283
Shares: 2,655,817 · Class: 8.24%
- Peter Evan HarwinReported CIK 0001663607
Shares: 7,249,356 · Class: 19.99%
- Tomas KiselakReported CIK 0001830177
Shares: 7,249,356 · Class: 19.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-062146
- Form type
- SCHEDULE 13D
- Filer
- Fairmount Funds Management LLC
- CIK
- CIK 1802528
- Filed
- May 01, 2025
- Reporting period
- Apr 28, 2025
- Description
- Schedule 13D beneficial ownership